Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
27
09
2023
accepted:
05
04
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
24
4
2024
Statut:
epublish
Résumé
Research on metastatic cancer has been hampered by limited sample availability. Here we present the breast cancer post-mortem tissue donation program UPTIDER and show how it enabled sampling of a median of 31 (range: 5-90) metastases and 5-8 liquids per patient from its first 20 patients. In a dedicated experiment, we show the mild impact of increasing time after death on RNA quality, transcriptional profiles and immunohistochemical staining in tumor tissue samples. We show that this impact can be counteracted by organ cooling. We successfully generated ex vivo models from tissue and liquid biopsies from distinct histological subtypes of breast cancer. We anticipate these and future findings of UPTIDER to elucidate mechanisms of disease progression and treatment resistance and to provide tools for the exploration of precision medicine strategies in the metastatic setting.
Identifiants
pubmed: 38658604
doi: 10.1038/s41523-024-00637-3
pii: 10.1038/s41523-024-00637-3
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31Subventions
Organisme : KU Leuven (Katholieke Universiteit Leuven)
ID : C14/21/114
Organisme : KU Leuven (Katholieke Universiteit Leuven)
ID : C14/18/092 and C14/22/125
Organisme : European Cooperation in Science and Technology (COST)
ID : LOBSTERPOT CA19138
Organisme : Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders)
ID : 1S76522N
Organisme : Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders)
ID : G0B6120N, G093821N
Organisme : Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders)
ID : 1802222N
Organisme : Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders)
ID : 1297322N
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : ITN-2019-859860-CANCERPREV
Informations de copyright
© 2024. The Author(s).
Références
Pasha, N. & Turner, N. C. Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nat. Cancer 2, 680–692 (2021).
pubmed: 35121946
doi: 10.1038/s43018-021-00229-1
Fumagalli, C. & Barberis, M. Breast cancer heterogeneity. Diagnostics 11, 1555 (2021).
pubmed: 34573897
pmcid: 8468623
doi: 10.3390/diagnostics11091555
Schrijver, W. A. M. E. et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J. Natl. Cancer Inst. 110, 568–580 (2018).
pubmed: 29315431
doi: 10.1093/jnci/djx273
Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).
pubmed: 32424352
pmcid: 7343625
doi: 10.1038/s41588-020-0628-z
Angus, L. et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet. 51, 1450–1458 (2019).
pubmed: 31570896
pmcid: 6858873
doi: 10.1038/s41588-019-0507-7
Bertucci, F. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560–564 (2019).
pubmed: 31118521
doi: 10.1038/s41586-019-1056-z
Brown, D. et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat. Commun. 8, 14944 (2017).
pubmed: 28429735
pmcid: 5474888
doi: 10.1038/ncomms14944
Garcia-Recio, S. et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat. Cancer 4, 128–147 (2023).
pubmed: 36585450
Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427–438.e6 (2018).
pubmed: 30205045
pmcid: 6327853
doi: 10.1016/j.ccell.2018.08.008
Aftimos, P. et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 11, 2796–2811 (2021).
pubmed: 34183353
pmcid: 9414283
doi: 10.1158/2159-8290.CD-20-1647
Zou, Y. et al. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: a systematic review and meta-analysis. EBioMedicine 63, 103137 (2021).
pubmed: 33310681
doi: 10.1016/j.ebiom.2020.103137
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).
pubmed: 33037194
pmcid: 7547708
doi: 10.1038/s41467-020-18794-x
Fendt, S. M., Frezza, C. & Erez, A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 10, 1797–1807 (2020).
pubmed: 33139243
pmcid: 7710573
doi: 10.1158/2159-8290.CD-20-0844
Geukens, T. et al. Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer. Eur. J. Cancer 188, 152–160 (2023).
pubmed: 37247580
doi: 10.1016/j.ejca.2023.04.026
Turner, N. C. et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 21, 1296–1308 (2020).
pubmed: 32919527
pmcid: 7599319
doi: 10.1016/S1470-2045(20)30444-7
Rothwell, D. G. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat. Med 25, 738–743 (2019).
pubmed: 31011204
doi: 10.1038/s41591-019-0380-z
Andre, F. et al. Genomics to select treatment for patients with metastatic breast cancer. Nature 610, 343–348 (2022).
pubmed: 36071165
doi: 10.1038/s41586-022-05068-3
Turner, N. C. et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann. Oncol. 34, 200–211 (2023).
pubmed: 36423745
doi: 10.1016/j.annonc.2022.11.005
Iacobuzio-Donahue, C. A. et al. Cancer biology as revealed by the research autopsy. Nat. Rev. Cancer https://doi.org/10.1038/s41568-019-0199-4 (2019).
Mannelli, C. Rapid Tissue Donation (RTD) for Oncology Research. 1–17 https://doi.org/10.1007/978-3-030-67201-0_1 (2021).
Duregon, E., Schneider, J., DeMarzo, A. M. & Hooper, J. E. Rapid research autopsy is a stealthy but growing contributor to cancer research. Cancer 125, 2915–2919 (2019).
pubmed: 31090935
doi: 10.1002/cncr.32184
Robb, T. J., Tse, R. & Blenkiron, C. Reviving the autopsy for modern cancer evolution research. Cancers 13 1–16 https://doi.org/10.3390/cancers13030409 (2021).
Dankner, M., Issa-Chergui, B. & Bouganim, N. Post-mortem tissue donation programs as platforms to accelerate cancer research. J. Pathol. Clin. Res. 6, 163–170 (2020).
pubmed: 32198850
pmcid: 7339213
doi: 10.1002/cjp2.159
Hessey, S. et al. Insights into the metastatic cascade through research autopsies. Trends Cancer 9, 490–502 (2023).
pubmed: 37059687
doi: 10.1016/j.trecan.2023.03.002
Rosenzweig, M. et al. The development and implementation of an autopsy/ tissue donation for breast cancer research. N. Bioeth. 27, 349–361 (2021).
doi: 10.1080/20502877.2021.1993608
Bacon, E. R., Ihle, K., Lee, P. P. & Waisman, J. R. Building a rapid autopsy program – a step-by-step logistics guide. Transl. Med. Commun. 5, 1–14 (2020).
doi: 10.1186/s41231-020-00074-x
Alsop, K. et al. A community-based model of rapid autopsy in end-stage cancer patients. Nat. Biotechnol. 34, 1010–1014 (2016).
pubmed: 27617737
doi: 10.1038/nbt.3674
Bavi, P. et al. Developing a pan-cancer research autopsy programme. J. Clin. Pathol. 72, 689–695 (2019).
pubmed: 31262953
doi: 10.1136/jclinpath-2019-205874
Rubin, M. A. et al. Rapid (‘warm’) autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 6, 1038–1045 (2000).
pubmed: 10741732
Kambhampati, M. et al. A standardized autopsy procurement allows for the comprehensive study of DIPG biology. Oncotarget 6, 12740–12747 (2015).
pubmed: 25749048
pmcid: 4494970
doi: 10.18632/oncotarget.3374
International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). https://www.who.int/standards/classifications/other-classifications/international-classification-of-diseases-for-oncology .
Fan, J. et al. Quantification of nucleic acid quality in postmortem tissues from a cancer research autopsy program. Oncotarget 7, 66906–66921 (2016).
pubmed: 27602498
pmcid: 5341846
doi: 10.18632/oncotarget.11836
Hatzis, C. et al. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J. Natl. Cancer Inst. 103, 1871–1883 (2011).
pubmed: 22034635
pmcid: 3243675
doi: 10.1093/jnci/djr438
Khoury, T. Delay to formalin fixation (cold ischemia time) effect on breast cancer molecules. Am. J. Clin. Pathol. 149, 275–292 (2018).
pubmed: 29471352
doi: 10.1093/ajcp/aqx164
Yildiz-Aktas, I. Z., Dabbs, D. J. & Bhargava, R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod. Pathol. 25, 1098–1105 (2012).
pubmed: 22460807
doi: 10.1038/modpathol.2012.59
Clevers, H. Modeling development and disease with organoids. Cell 165, 1586–1597 (2016).
pubmed: 27315476
doi: 10.1016/j.cell.2016.05.082
Messal, H. A., van Rheenen, J. & Scheele, C. L. G. J. An intravital microscopy toolbox to study mammary gland dynamics from cellular level to organ scale. J. Mammary Gland. Biol. Neoplasia 26, 9–27 (2021).
pubmed: 33945058
pmcid: 8217050
doi: 10.1007/s10911-021-09487-2
Zanella, E. R., Grassi, E. & Trusolino, L. Towards precision oncology with patient-derived xenografts. Nat. Rev. Clin. Oncol. 19, 719–732 (2022).
pubmed: 36151307
doi: 10.1038/s41571-022-00682-6
Roelofsen, L. M. et al. Protocol for ex vivo culture of patient-derived tumor fragments. STAR Protoc. 4, 102282 (2023).
pubmed: 37149855
pmcid: 10189508
doi: 10.1016/j.xpro.2023.102282
Sflomos, G. et al. A preclinical model for ERα-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell 29, 407–422 (2016).
pubmed: 26947176
doi: 10.1016/j.ccell.2016.02.002
Sflomos, G. et al. Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1. EMBO Mol. Med 13, e13180 (2021).
pubmed: 33616307
pmcid: 7933935
doi: 10.15252/emmm.202013180
Latacz, E. et al. Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. Br. J. Cancer 127, 988–1013 (2022).
pubmed: 35650276
pmcid: 9470557
doi: 10.1038/s41416-022-01859-7
Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 2021 27:7 27, 1250–1261 (2021).
Thommen, D. S. Tumour avatars to model patients’ responses to immunotherapy. Nat. Rev. Cancer 2022 1–1 https://doi.org/10.1038/s41568-022-00517-7 (2022).
Wu, J. M. et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin. Cancer Res. 14, 1938 (2008).
pubmed: 18381931
pmcid: 2965068
doi: 10.1158/1078-0432.CCR-07-4082
Roudier, M. P. et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol. 34, 646–653 (2003).
pubmed: 12874759
doi: 10.1016/S0046-8177(03)00190-4
Pisapia, D. J. et al. Next-generation rapid autopsies enable tumor evolution tracking and generation of preclinical models. JCO Precis Oncol. 1–13 https://doi.org/10.1200/po.16.00038 (2017).
Broniscer, A. et al. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 116, 4632–4637 (2010).
pubmed: 20589749
doi: 10.1002/cncr.25405
Chen, H. Z. et al. Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy. Oncotarget 10, 277 (2019).
pubmed: 30719225
pmcid: 6349455
doi: 10.18632/oncotarget.26352
Walker, D. G. et al. Characterization of RNA isolated from eighteen different human tissues: results from a rapid human autopsy program. Cell Tissue Bank 17, 361 (2016).
pubmed: 27083469
pmcid: 5026224
doi: 10.1007/s10561-016-9555-8
Grizzle, W. E., Otali, D., Sexton, K. C. & Atherton, D. S. Effects of cold ischemia on gene expression: a review and commentary. Biopreserv Biobank 14, 548 (2016).
pubmed: 27551929
pmcid: 5180081
doi: 10.1089/bio.2016.0013
Atherton, D. S., Sexton, K. C., Otali, D., Bell, W. C. & Grizzle, W. E. Factors affecting the use of human tissues in biomedical research: Implications in the design and operation of a biorepository. Methods Mol. Biol. 1381, 1–38 (2016).
pubmed: 26667452
doi: 10.1007/978-1-4939-3204-7_1
Harrison, P. J. et al. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci. Lett. 200, 151–154 (1995).
pubmed: 9064599
doi: 10.1016/0304-3940(95)12102-A
Birdsill, A. C., Walker, D. G., Lue, L. F., Sue, L. I. & Beach, T. G. Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank 12, 311–318 (2011).
pubmed: 20703815
doi: 10.1007/s10561-010-9210-8
Gupta, S., Halushka, M. K., Hilton, G. M. & Arking, D. E. Postmortem cardiac tissue maintains gene expression profile even after late harvesting. BMC Genom. 13, 26 (2012).
doi: 10.1186/1471-2164-13-26
Holen, I., Speirs, V., Morrissey, B. & Blyth, K. In vivo models in breast cancer research: progress, challenges and future directions. Dis. Model Mech. 10, 359 (2017).
pubmed: 28381598
pmcid: 5399571
doi: 10.1242/dmm.028274
Fiche, M. et al. Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions. J. Pathol. 247, 287–292 (2019).
pubmed: 30430577
doi: 10.1002/path.5200
Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inform. 95, 103208 (2019).
pubmed: 31078660
pmcid: 7254481
doi: 10.1016/j.jbi.2019.103208
Harris, P. A. et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 42, 377–381 (2009).
doi: 10.1016/j.jbi.2008.08.010
SEER ICD-O-3 Coding Materials. https://seer.cancer.gov/icd-o-3/ .
Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J. Clin. Oncol. 38, 1346–1366 (2020).
pubmed: 31928404
doi: 10.1200/JCO.19.02309
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
doi: 10.1093/bioinformatics/bts635
Liao, Y., Smyth, G. K. & Shi, W. FeatureCoUnts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677
doi: 10.1093/bioinformatics/btt656
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Ignatiadis, M. et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J. Clin. Oncol. 30, 1996–2004 (2012).
pubmed: 22508827
doi: 10.1200/JCO.2011.39.5624
Salmon, P. & Trono, D. Production and titration of lentiviral vectors. Curr. Protoc. Hum. Genet. Chapter 12, (2007).
Koorman, T. et al. Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment. Oncogene 41, 2458–2469 (2022).
pubmed: 35292774
pmcid: 9033577
doi: 10.1038/s41388-022-02258-1
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program | Code Ocean. https://codeocean.com/capsule/4516420/tree/v1 .